Moscow [Russia], May 17 (ANI): In a bid to speed up India's COVID-19 vaccination efforts, another Indian company, Shilpa Medicare has joined efforts to ramp up the manufacturing capacity of the Sputnik V vaccine.
Read more about Barometers hover near day s high; breadth remains strong on Business Standard. The benchmark indices hit intraday high in early afternoon trade. At 12:20 IST, the barometer index, the S&P BSE Sensex, surged 633.05 points or 1.30% at 49,365.60. The Nifty 50 index jumped 173.50 points or 1.18% at 14,851.30.
Shilpa Medicare share jumps 14% on deal for production of Sputnik V vaccine
The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production
BusinessToday.In | May 17, 2021 | Updated 17:55 IST
Shilpa Medicare share rose 14 per cent to hit an intraday high of Rs 764.45 on BSE today after the company announced that its wholly owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a 3-year definitive agreement with Dr. Reddy s Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.